US 12,110,291 B2
Glutarimide-containing pan-KRAS-mutant degrader compounds and uses thereof
Robert Luo, New City, NY (US); Ji Liu, Bellevue, WA (US); Pin Huang, Shanghai (CN); Jie Su, New York, NY (US); Yan Feng, Plainsboro, NJ (US); Ke Liu, Bellevue, WA (US); Jie Fan, New York, NY (US); Wei He, Zionsville, IN (US); and Yimin Qian, Plainsboro, NJ (US)
Assigned to Tiger Biotherapeutics Inc., Cranbury, NJ (US)
Filed by Tiger Biotherapeutics Inc., Cranbury, NJ (US)
Filed on Nov. 30, 2023, as Appl. No. 18/524,705.
Claims priority of provisional application 63/593,528, filed on Oct. 26, 2023.
Claims priority of provisional application 63/385,453, filed on Nov. 30, 2022.
Prior Publication US 2024/0217972 A1, Jul. 4, 2024
Int. Cl. C07D 471/04 (2006.01); C07D 519/00 (2006.01)
CPC C07D 471/04 (2013.01) [C07D 519/00 (2013.01)] 32 Claims
 
1. A compound, wherein the compound is represented by Formula IB′ or is a pharmaceutically acceptable salt thereof:

OG Complex Work Unit Chemistry
wherein:
each Rb is independently selected from halogen, hydroxy, amino, and C1-C4 alkyl;
n′ is 1 or 2;
R2 is H;
R3 is halogen;
Q is selected from

OG Complex Work Unit Chemistry
and
L is selected from

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry